Notably, the binding of the W1291R mutant to non-TET2 loci is the first report that mutations in CRTET2 can change its genomic localization, potentially opening the prospect that genomic mis-localization of CRTET2 mutants to non-target loci could serve as a biomarker for leukaemia. Here, TET2 is linked to leukemia.